GDGRU-DTA: Predicting Drug-Target Binding Affinity Based on GNN and Double GRU
Lyu Zhijian,Jiang Shaohua,Liang Yigao,Gao Min
DOI: https://doi.org/10.5121/csit.2022.120703
2022-04-25
Abstract:The work for predicting drug and target affinity(DTA) is crucial for drug development and repurposing. In this work, we propose a novel method called GDGRU-DTA to predict the binding affinity between drugs and targets, which is based on GraphDTA, but we consider that protein sequences are long sequences, so simple CNN cannot capture the context dependencies in protein sequences well. Therefore, we improve it by interpreting the protein sequences as time series and extracting their features using Gate Recurrent Unit(GRU) and Bidirectional Gate Recurrent Unit(BiGRU). For the drug, our processing method is similar to that of GraphDTA, but uses two different graph convolution methods. Subsequently, the representation of drugs and proteins are concatenated for final prediction. We evaluate the proposed model on two benchmark datasets. Our model outperforms some state-of-the-art deep learning methods, and the results demonstrate the feasibility and excellent feature capture ability of our model.
Quantitative Methods,Artificial Intelligence,Machine Learning
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the prediction of drug - target binding affinity (Drug - Target Affinity, DTA). Specifically, the author proposes a new method, GDGRU - DTA, aiming to predict the binding affinity between drugs and targets more accurately, thereby accelerating drug development and drug repositioning research.
### Background and Problem Description
The prediction of drug - target binding affinity is of great significance in drug development and drug repositioning. Traditional wet - experiment methods are time - consuming and costly, so virtual screening (Virtual Screening, VS) has become a method to accelerate drug discovery. However, existing VS methods such as structure - based VS, ligand - based VS and sequence - based VS all have their own limitations. For example, when the structural information of a protein is unknown, the structure - based method cannot work. In addition, many binary - classification - based methods can only provide a simple judgment on whether the drug and the target interact, ignoring the specific binding strength information, which is very important for drug repositioning and discovery.
### Research Motivation
To overcome the limitations of the above methods, the author proposes a new model, GDGRU - DTA, based on graph neural network (Graph Neural Network, GNN) and bidirectional gated recurrent unit (Bidirectional Gated Recurrent Unit, BiGRU). This model aims to improve the accuracy of DTA prediction by improving the protein sequence feature extraction method and better capturing the context - dependent relationships in long sequences.
### Main Contributions
1. **Improvement of Protein Sequence Feature Extraction**: Most existing methods use convolutional neural network (CNN) to extract protein sequence features, but CNN is difficult to effectively capture the context - dependent relationships in long sequences. GDGRU - DTA interprets the protein sequence as a time series and uses GRU and BiGRU to extract features, thereby better capturing the dependencies in long sequences.
2. **Drug Feature Extraction**: For drugs, GDGRU - DTA adopts two new graph convolution methods (GatedGraph and Transformer) to better capture the topological structure features of drug molecules.
3. **Performance Improvement**: The experimental results show that GDGRU - DTA performs better than existing deep - learning methods on two benchmark datasets (Davis and KIBA), especially achieving significant improvements in evaluation indicators such as MSE, CI and r²m.
### Conclusion
By introducing GRU/BiGRU and GNN, GDGRU - DTA can more effectively capture the complex relationships between drugs and targets, thereby improving the accuracy of DTA prediction. This method provides new tools and ideas for drug development and drug repositioning.
---
If you need more detailed formula derivations or specific technical implementation details, please let me know and I will further explain for you.